External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<div><div><div><ul><li>Clarity have provided an update regarding their SeCuRE trial – the PSMA theranostic trial assessing the identification and treatment of metastatic, castrate-resistant prostate cancer (mCRPC) using Clarity’s 64Cu/67Cu-SAR-bisPSMA targeted copper theranostic (TCT) pair.</li><li>The release of the early data reveal is positive – there were no safety issues reported with 67Cu (at a 4GBq dose level), meaning that the trial can progress to Cohort 2 (utilizing an 8GBq dose).</li><li>Importantly, even with the lower dose used in Cohort 1, there is already evidence of clinical</li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have provided an update regarding their SeCuRE trial – the PSMA theranostic trial assessing the identification and treatment of metastatic, castrate-resistant prostate cancer (mCRPC) using Clarity’s 64Cu/67Cu-SAR-bisPSMA targeted copper theranostic (TCT) pair.The release of the early data reveal is positive – there were no safety issues reported with 67Cu (at a 4GBq dose level), meaning that the trial can progress to Cohort 2 (utilizing an 8GBq dose).Importantly, even with the lower dose used in Cohort 1, there is already evidence of clinicalContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - First Look at 67Cu Therapy Data